Research on Malignancies in AIDS and Acquired Immune Suppression

Document Type:	Grants Notice
Funding Opportunity Number:	PA-04-157
Posted Date:	Sep 30, 2004
Original Due Date for Applications:	Multiple Receipt Dates - See Link to Full Announcement for details.
Current Due Date for Applications:	Multiple Receipt Dates - See Link to Full Announcement for details.
Archive Date:	Oct 02, 2007
Funding Instrument Type:	Grant
Category of Funding Activity:	Health Education
Expected Number of Awards:	8
Estimated Total Program Funding:	$2,000,000.00
Award Ceiling:	$200,000.00
Award Floor:	none
CFDA Number:	93.393 -- Cancer Cause and Prevention Research 93.121 -- Oral Diseases and Disorders Research 93.396 -- Cancer Biology Research
Cost Sharing or Matching Requirement:	No

Eligible Applicants

Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education

Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education

For profit organizations other than small businesses

Small businesses

Public and State controlled institutions of higher education

Private institutions of higher education

State governments

County governments

City or township governments

Special district governments

Independent school districts

Native American tribal governments (Federally recognized)

Public housing authorities/Indian housing authorities

Native American tribal organizations (other than Federally recognized tribal governments)

Others (see text field entitled "Additional Information on Eligibility" for clarification)

Additional Information on Eligibility:


Eligible agencies of the Federal Government are eligible to apply.

Foreign institutions are eligible to apply.

Agency Name

Description

The purpose of this initiative is to stimulate research that will improve our understanding of the biological basis of development and progression of cancer in the context of Human Immunodeficiency Virus (HIV) infection and Acquired Immune Deficiency Syndrome (AIDS) or acquired immune suppression not associated with HIV infection such as organ transplantation. The NCI and NIDCR seek to encourage novel approaches to discovery and preclinical development of novel therapeutic agents and biomarkers for early diagnosis and monitoring of disease progression. Molecular epidemiologic studies of the role of chronic latent viruses and their interaction with one another or with environmental factors in the context of acquired immune suppression or HIV infection leading to the development of tumors or lesions with oncogenic potential are also of interest. This PA will use the NIH exploratory/development (R21) award mechanism and the NIH investigator-initiated research project grants (R0!
1) award mechanism. Please see the link at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-041.html   for the NIH policy on submitting revised applications . It is anticipated that 2 million in total costs will be awarded in the first year to fund 8  12 applications. Application material and instructions are available at http://grants.nih.gov/grants/funding/phs398/phs398.html in an interactive format.

Link to Full Announcement

http://grants.nih.gov/grants/guide/pa-files/PA-04-157.html

If you have difficulty accessing the full announcement electronically, please contact:

If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster NIH OER Webmaster

• HHS NIH listed by [Posted Date]
• HHS Agencywide listed by [Posted Date]